BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson's Disease. Semin Neurol 2017;37:147-57. [PMID: 28511255 DOI: 10.1055/s-0037-1602423] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Dos Santos EUD, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular Med 2019;21:295-302. [PMID: 31119645 DOI: 10.1007/s12017-019-08549-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States. BMC Neurol 2021;21:46. [PMID: 33516182 DOI: 10.1186/s12883-021-02074-2] [Reference Citation Analysis]
3 El-Battari A, Rodriguez L, Chahinian H, Delézay O, Fantini J, Yahi N, Di Scala C. Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells. Int J Mol Sci 2021;22:11550. [PMID: 34768981 DOI: 10.3390/ijms222111550] [Reference Citation Analysis]
4 Dos Santos EUD, da Silva IIFG, Asano AGC, Asano NMJ, De Mascena Diniz Maia M, de Souza PRE. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. Mol Biol Rep 2020;47:8997-9004. [PMID: 33151475 DOI: 10.1007/s11033-020-05956-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Omoruyi SI, Ibrakaw AS, Ekpo OE, Boatwright JS, Cupido CN, Hussein AA. Neuroprotective Activities of Crossyne flava Bulbs and Amaryllidaceae Alkaloids: Implications for Parkinson's Disease. Molecules 2021;26:3990. [PMID: 34208814 DOI: 10.3390/molecules26133990] [Reference Citation Analysis]
6 Levin OS, Iakovleva OV, Coloman II, Kuzmina AV. Could New Generations of Sensors Reshape the Management of Parkinson’s Disease? CTN 2021;5:18. [DOI: 10.3390/ctn5020018] [Reference Citation Analysis]
7 Tunur T, DeBlois A, Yates-Horton E, Rickford K, Columna LA. Augmented reality-based dance intervention for individuals with Parkinson's disease: A pilot study. Disabil Health J 2020;13:100848. [PMID: 31679951 DOI: 10.1016/j.dhjo.2019.100848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jhuo CF, Hsieh SK, Chen CJ, Chen WY, Tzen JTC. Teaghrelin Protects SH-SY5Y Cells against MPP+-Induced Neurotoxicity through Activation of AMPK/SIRT1/PGC-1α and ERK1/2 Pathways. Nutrients 2020;12:E3665. [PMID: 33260513 DOI: 10.3390/nu12123665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bhattarai Y, Kashyap PC. Parkinson's disease: Are gut microbes involved? Am J Physiol Gastrointest Liver Physiol 2020;319:G529-40. [PMID: 32877215 DOI: 10.1152/ajpgi.00058.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kleiner G, Fernandez HH, Chou KL, Fasano A, Duque KR, Hengartner D, Law A, Margolius A, Poon Y, Sáenz Farret M, Saleh P, Vizcarra JA, Stebbins GT, Espay AJ; PSG NoMoFA Study Group. Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire. Mov Disord 2021;36:1392-400. [DOI: 10.1002/mds.28507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Kwon M, Cheong MJ, Leem J, Kim TH. Effect of Acupuncture on Movement Function in Patients with Parkinson's Disease: Network Meta-Analysis of Randomized Controlled Trials. Healthcare (Basel) 2021;9:1502. [PMID: 34828548 DOI: 10.3390/healthcare9111502] [Reference Citation Analysis]
12 Carrarini C, Russo M, Dono F, Di Pietro M, Rispoli MG, Di Stefano V, Ferri L, Barbone F, Vitale M, Thomas A, Sensi SL, Onofrj M, Bonanni L. A Stage-Based Approach to Therapy in Parkinson's Disease. Biomolecules 2019;9:E388. [PMID: 31434341 DOI: 10.3390/biom9080388] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
13 Yoshida K, Takano K, Tani H, Nobuhara S, Maruyama Y, Marumoto K. ΔHR/ΔWR derived from CPET; A novel predictor of 'off' symptom in Parkinson's disease. Parkinsonism Relat Disord 2021;92:101-4. [PMID: 34739978 DOI: 10.1016/j.parkreldis.2021.10.022] [Reference Citation Analysis]
14 Hwang H, Norris SA. Managing Advanced Parkinson Disease. J Geriatr Psychiatry Neurol 2021;34:289-300. [PMID: 34219527 DOI: 10.1177/08919887211018277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Dos Santos EUD, Sampaio TF, Tenório Dos Santos AD, Bezerra Leite FC, da Silva RC, Crovella S, Asano AGC, Asano NMJ, de Souza PRE. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. J Pharm Pharmacol 2019;71:206-12. [PMID: 30353564 DOI: 10.1111/jphp.13031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Sica M, Tedesco S, Crowe C, Kenny L, Moore K, Timmons S, Barton J, O'Flynn B, Komaris DS. Continuous home monitoring of Parkinson's disease using inertial sensors: A systematic review. PLoS One 2021;16:e0246528. [PMID: 33539481 DOI: 10.1371/journal.pone.0246528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kwok JYY, Lee JJ, Choi EPH, Chau PH, Auyeung M. Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson's disease. BMC Complement Med Ther 2022;22:37. [PMID: 35130894 DOI: 10.1186/s12906-022-03519-y] [Reference Citation Analysis]
18 Shoshan-Barmatz V, Anand U, Nahon-Crystal E, Di Carlo M, Shteinfer-Kuzmine A. Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target? Front Physiol 2021;12:730048. [PMID: 34671273 DOI: 10.3389/fphys.2021.730048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 He JM, Wu ZB, Cai NQ, Lin Y. Levodopa-Induced Ocular Dyskinesia in an Early-Onset Parkinson Disease Patient With GBA Mutation. Clin Neuropharmacol 2021;44:201-4. [PMID: 34654015 DOI: 10.1097/WNF.0000000000000484] [Reference Citation Analysis]
20 Abraham ME, Gold J, Dondapati A, Gendreau J, Mammis A, Herschman Y. Intrathecal and intracerebroventricular dopamine for Parkinson's disease. Clin Neurol Neurosurg 2021;200:106374. [PMID: 33290887 DOI: 10.1016/j.clineuro.2020.106374] [Reference Citation Analysis]
21 Hatano T, Kano O, Sengoku R, Yoritaka A, Suzuki K, Nishikawa N, Mukai Y, Nomura K, Yoshida N, Seki M, Matsukawa MK, Terashi H, Kimura K, Tashiro J, Hirano S, Murakami H, Joki H, Uchiyama T, Shimura H, Ogaki K, Fukae J, Tsuboi Y, Takahashi K, Yamamoto T, Yanagisawa N, Nagayama H. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study. BMC Neurol 2022;22:71. [PMID: 35241003 DOI: 10.1186/s12883-022-02600-w] [Reference Citation Analysis]
22 Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kägi G, Raw J, Stefani A, Warnecke T, Jost WH; SYNAPSES Study Investigators Group. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis 2021;11:187-98. [PMID: 33104040 DOI: 10.3233/JPD-202224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
23 Jaramillo-jimenez A, Ying Y, Ren P, Xiao Z, Zhang Q, Wang J, Rong H, Borda MG, Bonanni L, Aarsland D, Wu D. Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report. Front Neurol 2022;13:839539. [DOI: 10.3389/fneur.2022.839539] [Reference Citation Analysis]
24 Qian Y, Zhang Y, He X, Xu S, Yang X, Mo C, Lu X, Qiu M, Xiao Q. Findings in Chinese Patients With Parkinson's Disease: A Content Analysis From the SML Study. Front Psychiatry 2021;12:615743. [PMID: 33603686 DOI: 10.3389/fpsyt.2021.615743] [Reference Citation Analysis]
25 Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Zangaglia R, Bentivoglio A, Eleopra R, Gualberti G, Melzi G, Antonini A. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 2019;266:2164-76. [PMID: 31134377 DOI: 10.1007/s00415-019-09337-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
26 Frampton JE. Rotigotine Transdermal Patch: A Review in Parkinson’s Disease. CNS Drugs 2019;33:707-18. [DOI: 10.1007/s40263-019-00646-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
27 Aich S, Youn J, Chakraborty S, Pradhan PM, Park JH, Park S, Park J. A Supervised Machine Learning Approach to Detect the On/Off State in Parkinson's Disease Using Wearable Based Gait Signals. Diagnostics (Basel) 2020;10:E421. [PMID: 32575764 DOI: 10.3390/diagnostics10060421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Saba RA, Maia DP, Cardoso FEC, Borges V, F. Andrade LA, Ferraz HB, Barbosa ER, Rieder CRDM, da Silva DJ, Chien HF, Capato T, Rosso AL, Souza Lima CF, Bezerra JMF, Nicaretta D, Povoas Barsottini OG, Godeiro-júnior C, Broseghini Barcelos L, Gisbert Cury R, Spitz M, Azevedo Silva SMC, Della Colletta MV. Guidelines for Parkinson’s disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms. Arq Neuro-Psiquiatr . [DOI: 10.1590/0004-282x-anp-2021-0219] [Reference Citation Analysis]